Aiwell Japan operates in the healthcare and biotechnology sectors, specializing in AI-driven proteomics technology. The company collaborates with Tokyo Institute of Technology and other institutions to analyze proteins from trace amounts of samples, enabling early detection and prevention of illnesses. Aiwell Japan's core services support drug discovery, diagnosis, and remote medical care by leveraging advanced digital imaging and AI to compare mass image data. The company serves pharmaceutical companies, research institutions, and healthcare providers. Its business model involves offering specialized analytical services and solutions, generating revenue through service contracts and partnerships. Aiwell Japan aims to create a sustainable healthy society by making health visible through high-quality data banks and innovative biological judgment technology.

Keywords: AI proteomics, drug discovery, diagnosis, remote medical care, protein analysis, digital imaging, healthcare, biotechnology, data banks, early detection.